Identifying risk for attrition during treatment for depression.

Journal Article (Journal Article)

BACKGROUND: Understanding patients' ambivalence about treatment persistence may be useful in tailoring retention interventions for individual patients with major depressive disorder. METHODS: Participants (n = 265) with major depressive disorder were enrolled into an 8-week trial with a selective serotonin reuptake inhibitor. At baseline and week 2, the participants were asked about their intent to return for the next visit, complete the study and continue in the study should they experience side effects or no improvement. Dropouts were defined as participants who discontinued attending clinic visits before completing the trial. RESULTS: Participants who at baseline reported an uncertain/negative intent to continue if they experienced side effects or no improvement dropped out at a significantly higher rate by weeks 6 and 8. Uncertain/negative intent at week 2 predicted attrition at all following visits. Dropouts without side effects were more likely to have reported an uncertain/negative intent to attend at both baseline and week 2, while dropouts who experienced side effects were more likely to have reported an uncertain/negative intent to attend only at baseline. Positive intent to continue was associated with greater symptom improvement in both dropouts and completers despite the possibility of lack of efficacy. CONCLUSIONS: Participants' pretreatment concerns about continuing antidepressant treatment in the presence of side effects signals challenges to the completion of a full 8-week acute phase treatment, even if the participant does not develop side effects. Individualized review of concerns and tailoring appropriate interventions may be necessary to reduce attrition.

Full Text

Duke Authors

Cited Authors

  • Warden, D; Trivedi, MH; Wisniewski, SR; Lesser, IM; Mitchell, J; Balasubramani, GK; Fava, M; Shores-Wilson, K; Stegman, D; Rush, AJ

Published Date

  • 2009

Published In

Volume / Issue

  • 78 / 6

Start / End Page

  • 372 - 379

PubMed ID

  • 19738403

Pubmed Central ID

  • PMC2820313

Electronic International Standard Serial Number (EISSN)

  • 1423-0348

Digital Object Identifier (DOI)

  • 10.1159/000235977


  • eng

Conference Location

  • Switzerland